# Multiplatform molecular test performance in indeterminate thyroid nodules

Source: https://onco.cc/key-papers/paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020/  
OnCo record `paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A multicentre study of a combined DNA, RNA and microRNA test on uncertain thyroid nodules.

## Summary

The multiplatform test had 95 per cent sensitivity, 90 per cent specificity, a 97 per cent negative predictive value and a 75 per cent positive predictive value.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Diagnostic Cytopathology
- Year: 2020
- DOI: 10.1002/dc.24564
- Authors: Lupo MA, Walts AE, Sistrunk JW, et al.
- Findings: Sensitivity 95%, specificity 90%, negative predictive value 97%, positive predictive value 75%.
- What it means: Adding microRNA to DNA and RNA fusion testing gave high negative predictive value.
- Caveats: Industry-sponsored.

## Sources

- Lupo et al., Diagn Cytopathol 2020: https://doi.org/10.1002/dc.24564
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32767735/

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Thyroid nodule FNA, Bethesda cytology & molecular classifiers](https://onco.cc/technologies/thyroid-fna-molecular/)
- drugs: [ThyGeNEXT and ThyraMIR v2](https://onco.cc/drugs/thygenext-thyramir/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020.json